Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Infarction | 12 | 2024 | 475 | 3.680 |
Why?
|
| Acute Coronary Syndrome | 7 | 2024 | 196 | 3.390 |
Why?
|
| Chest Pain | 12 | 2024 | 208 | 1.750 |
Why?
|
| Troponin T | 7 | 2024 | 81 | 1.590 |
Why?
|
| Cardiology | 5 | 2024 | 99 | 1.510 |
Why?
|
| Troponin | 8 | 2024 | 106 | 1.410 |
Why?
|
| Emergency Medical Services | 5 | 2023 | 178 | 1.310 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 90 | 0.970 |
Why?
|
| Adult | 30 | 2024 | 9345 | 0.900 |
Why?
|
| Mortality | 2 | 2020 | 125 | 0.850 |
Why?
|
| Prospective Studies | 15 | 2024 | 2282 | 0.820 |
Why?
|
| Emergency Service, Hospital | 11 | 2024 | 474 | 0.810 |
Why?
|
| Nursing Staff | 1 | 2022 | 8 | 0.810 |
Why?
|
| Genital Neoplasms, Female | 6 | 2017 | 17 | 0.790 |
Why?
|
| Humans | 54 | 2024 | 32005 | 0.790 |
Why?
|
| Hospitalization | 3 | 2023 | 470 | 0.770 |
Why?
|
| Middle Aged | 34 | 2024 | 11817 | 0.760 |
Why?
|
| Predictive Value of Tests | 7 | 2024 | 876 | 0.730 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 215 | 0.730 |
Why?
|
| Hypercholesterolemia | 3 | 2023 | 70 | 0.630 |
Why?
|
| Ethnic Groups | 1 | 2020 | 476 | 0.600 |
Why?
|
| Female | 34 | 2024 | 19959 | 0.590 |
Why?
|
| Head and Neck Neoplasms | 5 | 2022 | 130 | 0.570 |
Why?
|
| Deglutition Disorders | 2 | 2014 | 51 | 0.560 |
Why?
|
| Male | 26 | 2024 | 19165 | 0.520 |
Why?
|
| Mass Screening | 3 | 2023 | 263 | 0.520 |
Why?
|
| Aged | 23 | 2024 | 10301 | 0.490 |
Why?
|
| Models, Statistical | 1 | 2014 | 175 | 0.440 |
Why?
|
| Neoplasms | 4 | 2024 | 726 | 0.410 |
Why?
|
| Gynecologic Surgical Procedures | 3 | 2017 | 47 | 0.390 |
Why?
|
| Treatment Outcome | 7 | 2017 | 3306 | 0.380 |
Why?
|
| Death | 4 | 2024 | 49 | 0.370 |
Why?
|
| Algorithms | 5 | 2024 | 495 | 0.360 |
Why?
|
| Coronary Artery Disease | 2 | 2024 | 401 | 0.340 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2018 | 11 | 0.320 |
Why?
|
| North Carolina | 7 | 2023 | 1514 | 0.310 |
Why?
|
| Cohort Studies | 10 | 2024 | 1817 | 0.300 |
Why?
|
| Atherosclerosis | 2 | 2023 | 766 | 0.280 |
Why?
|
| Caregivers | 3 | 2024 | 114 | 0.280 |
Why?
|
| Postoperative Complications | 3 | 2017 | 780 | 0.270 |
Why?
|
| Quality of Life | 6 | 2022 | 946 | 0.270 |
Why?
|
| Decision Making | 2 | 2022 | 195 | 0.270 |
Why?
|
| Tamoxifen | 2 | 2017 | 59 | 0.260 |
Why?
|
| Young Adult | 11 | 2024 | 2636 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 458 | 0.260 |
Why?
|
| Odds Ratio | 4 | 2020 | 472 | 0.260 |
Why?
|
| Cardiovascular Diseases | 3 | 2022 | 1128 | 0.250 |
Why?
|
| Logistic Models | 4 | 2020 | 781 | 0.240 |
Why?
|
| Retrospective Studies | 11 | 2023 | 3509 | 0.240 |
Why?
|
| United States | 5 | 2024 | 3939 | 0.230 |
Why?
|
| Consensus | 1 | 2024 | 85 | 0.230 |
Why?
|
| Government Programs | 1 | 2023 | 9 | 0.220 |
Why?
|
| Rural Population | 2 | 2023 | 274 | 0.220 |
Why?
|
| Colonoscopy | 1 | 2023 | 45 | 0.220 |
Why?
|
| Hyperlipidemias | 1 | 2023 | 54 | 0.210 |
Why?
|
| Adolescent | 9 | 2023 | 3539 | 0.210 |
Why?
|
| Primary Health Care | 2 | 2022 | 227 | 0.210 |
Why?
|
| Risk Factors | 8 | 2024 | 3876 | 0.210 |
Why?
|
| Tablets | 1 | 2022 | 11 | 0.210 |
Why?
|
| Risk Assessment | 7 | 2024 | 1426 | 0.200 |
Why?
|
| Olfaction Disorders | 1 | 2021 | 7 | 0.200 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 33 | 0.190 |
Why?
|
| Cross Infection | 1 | 2021 | 55 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2014 | 154 | 0.190 |
Why?
|
| Coronary Disease | 1 | 2022 | 211 | 0.190 |
Why?
|
| Bacteremia | 1 | 2021 | 65 | 0.190 |
Why?
|
| Staphylococcal Infections | 1 | 2021 | 77 | 0.190 |
Why?
|
| Smoking Cessation | 1 | 2023 | 198 | 0.180 |
Why?
|
| Time Factors | 6 | 2024 | 2149 | 0.180 |
Why?
|
| Testicular Neoplasms | 1 | 2020 | 15 | 0.180 |
Why?
|
| Teratoma | 1 | 2020 | 10 | 0.180 |
Why?
|
| Ambulances | 1 | 2020 | 13 | 0.180 |
Why?
|
| Naloxone | 1 | 2020 | 26 | 0.170 |
Why?
|
| Transportation of Patients | 1 | 2020 | 26 | 0.170 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 39 | 0.170 |
Why?
|
| Preventive Health Services | 1 | 2020 | 44 | 0.170 |
Why?
|
| Medical Oncology | 2 | 2018 | 86 | 0.170 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 167 | 0.170 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 762 | 0.170 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 128 | 0.170 |
Why?
|
| Lymph Nodes | 1 | 2020 | 107 | 0.170 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 1531 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 16 | 0.160 |
Why?
|
| Sex Factors | 1 | 2020 | 663 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2020 | 162 | 0.150 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 240 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 232 | 0.150 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2017 | 1 | 0.140 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2017 | 4 | 0.140 |
Why?
|
| Estrogen Antagonists | 1 | 2017 | 17 | 0.140 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 27 | 0.140 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 23 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 22 | 0.140 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 1166 | 0.130 |
Why?
|
| Esophagectomy | 1 | 2015 | 15 | 0.130 |
Why?
|
| Esophagogastric Junction | 1 | 2015 | 7 | 0.130 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2015 | 1 | 0.130 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 35 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 42 | 0.130 |
Why?
|
| Gastrectomy | 1 | 2015 | 68 | 0.130 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 84 | 0.120 |
Why?
|
| Upper Extremity Deep Vein Thrombosis | 1 | 2015 | 7 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 261 | 0.120 |
Why?
|
| Alleles | 1 | 2015 | 248 | 0.120 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 209 | 0.120 |
Why?
|
| Anxiety | 1 | 2016 | 191 | 0.120 |
Why?
|
| Catheterization, Central Venous | 1 | 2015 | 62 | 0.120 |
Why?
|
| Preoperative Period | 1 | 2014 | 35 | 0.120 |
Why?
|
| Hispanic Americans | 1 | 2020 | 940 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 31 | 0.120 |
Why?
|
| Lymphoma | 1 | 2014 | 35 | 0.120 |
Why?
|
| Health Services | 1 | 2014 | 38 | 0.110 |
Why?
|
| Religion and Medicine | 1 | 2013 | 19 | 0.110 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2013 | 13 | 0.110 |
Why?
|
| Esophageal Stenosis | 1 | 2013 | 6 | 0.110 |
Why?
|
| Dilatation | 1 | 2013 | 8 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2013 | 23 | 0.110 |
Why?
|
| Esophagoscopy | 1 | 2013 | 19 | 0.110 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 3990 | 0.110 |
Why?
|
| African Americans | 1 | 2020 | 1425 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2014 | 220 | 0.110 |
Why?
|
| Cell Separation | 1 | 2013 | 92 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 2265 | 0.110 |
Why?
|
| Papillomavirus Vaccines | 1 | 2013 | 44 | 0.110 |
Why?
|
| Survivors | 1 | 2014 | 163 | 0.110 |
Why?
|
| Parents | 1 | 2013 | 147 | 0.100 |
Why?
|
| Attitude to Health | 1 | 2013 | 165 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 134 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 172 | 0.100 |
Why?
|
| Deglutition | 1 | 2011 | 29 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 1 | 2011 | 67 | 0.100 |
Why?
|
| Acute Disease | 2 | 2021 | 253 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 765 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 684 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 582 | 0.080 |
Why?
|
| Obesity | 1 | 2014 | 1175 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 753 | 0.070 |
Why?
|
| Postoperative Period | 2 | 2016 | 97 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 767 | 0.060 |
Why?
|
| Prognosis | 2 | 2020 | 1497 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2024 | 163 | 0.050 |
Why?
|
| Workplace | 1 | 2023 | 49 | 0.050 |
Why?
|
| Coronary Angiography | 1 | 2023 | 153 | 0.050 |
Why?
|
| Phenotype | 2 | 2015 | 632 | 0.050 |
Why?
|
| Lipoprotein(a) | 1 | 2022 | 21 | 0.050 |
Why?
|
| Health Education | 1 | 2023 | 157 | 0.050 |
Why?
|
| Heart | 1 | 2023 | 177 | 0.050 |
Why?
|
| Cholesterol | 1 | 2023 | 252 | 0.050 |
Why?
|
| Lactoferrin | 1 | 2021 | 3 | 0.050 |
Why?
|
| Taste Disorders | 1 | 2021 | 4 | 0.050 |
Why?
|
| Lipids | 1 | 2023 | 232 | 0.050 |
Why?
|
| Taste | 1 | 2021 | 17 | 0.050 |
Why?
|
| Infection Control | 1 | 2021 | 28 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 173 | 0.050 |
Why?
|
| Focus Groups | 1 | 2022 | 113 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 423 | 0.050 |
Why?
|
| Smell | 1 | 2021 | 48 | 0.050 |
Why?
|
| Health Promotion | 1 | 2023 | 246 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2022 | 167 | 0.050 |
Why?
|
| Child | 2 | 2020 | 2438 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2022 | 293 | 0.050 |
Why?
|
| Age Factors | 1 | 2024 | 1188 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 44 | 0.040 |
Why?
|
| Orchiectomy | 1 | 2020 | 12 | 0.040 |
Why?
|
| Bleomycin | 1 | 2020 | 10 | 0.040 |
Why?
|
| Etoposide | 1 | 2020 | 34 | 0.040 |
Why?
|
| Retroperitoneal Space | 1 | 2020 | 20 | 0.040 |
Why?
|
| Life Support Care | 1 | 2020 | 14 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2021 | 185 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2020 | 18 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 545 | 0.040 |
Why?
|
| Cisplatin | 1 | 2020 | 76 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2020 | 59 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 89 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 166 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 220 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 517 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 206 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2020 | 671 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 1328 | 0.040 |
Why?
|
| Women's Health Services | 1 | 2016 | 11 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2016 | 32 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 1061 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 125 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 317 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2017 | 147 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 1269 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 412 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2020 | 605 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 146 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 322 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 367 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 298 | 0.030 |
Why?
|
| Attitude | 1 | 2014 | 40 | 0.030 |
Why?
|
| Patient Preference | 1 | 2014 | 47 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 733 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2014 | 58 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 399 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2014 | 69 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 170 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 877 | 0.030 |
Why?
|
| Linear Models | 1 | 2014 | 447 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2014 | 126 | 0.030 |
Why?
|
| Internet | 1 | 2014 | 195 | 0.030 |
Why?
|
| Depression | 1 | 2016 | 444 | 0.030 |
Why?
|
| Neck Dissection | 1 | 2011 | 9 | 0.020 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2011 | 6 | 0.020 |
Why?
|
| Laryngeal Neoplasms | 1 | 2011 | 15 | 0.020 |
Why?
|
| Gastrostomy | 1 | 2011 | 17 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1199 | 0.020 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2011 | 18 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 78 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 190 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2011 | 199 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 560 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 881 | 0.020 |
Why?
|